Syndax Pharmaceuticals Inc (SNDX)

Syndax Pharmaceuticals' stock price has been impacted by strong financial results, particularly the robust fourth quarter and full-year 2025 results. FDA approvals and pipeline advancements, such as the approval of Revuforj for R/R NPM1-mutated AML and the progress in clinical programs, have also positively influenced the stock. Analyst optimism, with multiple Wall Street firms raising price targets for SNDX, has contributed to a "Moderate Buy" consensus rating. Inducement grants reported by Syndax Pharmaceuticals signal active commercial-stage expansion. Insider selling has occurred over the past three months, with sales totaling $628,332.00. The company experienced an approximately 8% decline in share price due to investor concerns stemming from an expanded boxed warning.

There is no explicit information indicating significant demand seasonality for Syndax Pharmaceuticals' products. The available data suggests strong and accelerating demand with consistent quarter-over-quarter sales growth. The company anticipates continued growth for both products, driven by label expansion, increased duration of therapy, and broader prescriber adoption.

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on advancing cancer therapies. The company operates within the Healthcare sector, specifically in the Biotechnology industry and the broader Pharmaceutical Preparations sector. Syndax focuses on discovering, developing, and commercializing medicines that target defined molecular or immunologic drivers of disease. Its major products include Revuforj, an FDA-approved oral menin inhibitor for the treatment of relapsed or refractory acute leukemias, Niktimvo, an FDA-approved CSF-1R-blocking antibody for chronic graft-versus-host disease, and Entinostat, a selective HDAC inhibitor currently in late-stage clinical trials for hormone receptor-positive breast cancer and other solid tumors.

Syndax Pharmaceuticals' activities are primarily anchored in the United States. However, the company is expanding its reach internationally through a multi-regional managed access program for Revuforj, aiming to provide access to the drug in certain regions outside the U.S. where it is not commercially available, including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa.

Syndax Pharmaceuticals has cultivated a positive brand reputation, particularly in the past year, driven by its advancements in cancer therapies. Revuforj was named "Best New Drug" at the Scrip Awards in December 2025. The company emphasizes its commitment to patients and science, aiming to extend and improve the lives of cancer patients through scientific excellence and collaboration. The successful launches and accelerating demand for Revuforj and Niktimvo contribute to a strong reputation within the oncology community. An expanded boxed warning for one of its products led to an approximately 8% decline in share price.

Syndax Pharmaceuticals, Inc. is predominantly owned by institutional shareholders, with 235 institutional owners holding a total of 99,160,724 shares as of April 7, 2026, representing approximately 76.26% of the company's stock. Major institutional holders include BlackRock, Inc., Kynam Capital Management, LP, and Vanguard Group Inc. MPM Bioventures IV Qp LP is noted as the largest individual shareholder, owning 2.17 million shares, representing 2.46% of the company. Insiders own approximately 1.67% of the stock.